Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 1/20 | 0.44 |
| ▸ | PDE1A | P54750 | 1/20 | 0.44 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.44 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.44 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.44 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.44 |
| ▸ | PRMT5 | O14744 | 3/20 | 0.35 |
| ▸ | WDR77 | Q9BQA1 | 2/20 | 0.35 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | PARP1 | P09874 | 6/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25219373 | 0.85 | PRMT5 (0.35) | ADORA1PDE1APDE1BPDE3BPDE1C | |
| SCHEMBL31496951 | 0.85 | PRMT5 (0.46) | PRMT5WDR77 | |
| SCHEMBL30833177 | 0.85 | PRMT5 (0.35) | ADORA1PDE1APDE1BPDE3BPDE1C | |
| SCHEMBL23087910 | 0.82 | ADORA1 (0.53) | ADORA1PDE1APDE1BPDE3BPDE1C | |
| SCHEMBL23087259 | 0.82 | ADORA1 (0.44) | ADORA1PDE1APDE1BPDE3BPDE1C | |
| SCHEMBL30833185 | 0.82 | POLB (0.50) | ADORA1PDE1APDE1BPDE3BPDE1C | |
| SCHEMBL25223292 | 0.82 | POLB (0.50) | ADORA1PDE1APDE1BPDE3BPDE1C | |
| SCHEMBL29915107 | 0.79 | ADORA1 (0.42) | ADORA1PDE1APDE1BPDE3BPDE1C | |
| SCHEMBL27002205 | 0.79 | ADORA1 (0.42) | ADORA1PDE1APDE1BPDE3BPDE1C | |
| SCHEMBL23087438 | 0.75 | KDM4E (0.43) | ADORA1PDE1APDE1BPDE3BPDE1C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119585261-A | PRMT5 inhibitor, preparation method and application thereof | 上海艾力斯医药科技股份有限公司 | 2025-03-07 | — | — | CN | disclosed |
| US-20240208912-A1 | MTA-Cooperative PRMT5 Inhibitors | MIRATI THERAPEUTICS INC (US) | 2024-06-27 | — | — | US | disclosed |
| US-20240208912-A1 | MTA-Cooperative PRMT5 Inhibitors | MIRATI THERAPEUTICS INC (US) | 2024-06-27 | — | — | US | disclosed |
| WO-2024027703-A1 | PRMT5 INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF | 上海艾力斯医药科技股份有限公司 | 2024-02-08 | — | — | WO | disclosed |
| EP-4304720-A1 | MTA-COOPERATIVE PRMT5 INHIBITORS | Mirati Therapeutics, Inc. (US) | 2024-01-17 | — | — | EP | disclosed |
| US-20230054883-A1 | MTA-Cooperative PRMT5 Inhibitors | Mirati Therapeutics, Inc. | 2023-02-23 | — | — | US | disclosed |
| US-11492351-B2 | MTA-cooperative PRMT5 inhibitors | Mirati Therapeutics, Inc. (US) | 2022-11-08 | — | — | US | disclosed |
| US-11479551-B2 | MTA-cooperative PRMT5 inhibitors | Mirati Therapeutics, Inc. (US) | 2022-10-25 | — | — | US | disclosed |
| WO-2022192745-A1 | MTA-COOPERATIVE PRMT5 INHIBITORS | Mirati Therapeutics, Inc. (US) | 2022-09-15 | — | — | WO | disclosed |
| EP-4028388-A1 | MTA-COOPERATIVE PRMT5 INHIBITORS | Mirati Therapeutics, Inc. (US) | 2022-07-20 | — | — | EP | disclosed |
| CN-114728912-A | MTA-synergistic PRMT5 inhibitors | 米拉蒂医疗股份有限公司 | 2022-07-08 | — | — | CN | disclosed |
| US-20210079003-A1 | MTA-Cooperative PRMT5 Inhibitors | Mirati Therapeutics, Inc. | 2021-03-18 | — | — | US | disclosed |
| US-20210078994-A1 | MTA-Cooperative PRMT5 Inhibitors | Mirati Therapeutics, Inc. | 2021-03-18 | — | — | US | disclosed |
| WO-2021050915-A1 | MTA-COOPERATIVE PRMT5 INHIBITORS | Mirati Therapeutics, Inc. (US) | 2021-03-18 | — | — | WO | disclosed |
| WO-2021050915-A1 | MTA-COOPERATIVE PRMT5 INHIBITORS | Mirati Therapeutics, Inc. (US) | 2021-03-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11479551-B2 | MTA-cooperative PRMT5 inhibitors | PRMT5, PRMT1, PRMT3 | ADORA1 3515/4885PDE1A 1483/4885PDE1B 1584/4885 |
| US-20240208912-A1 | MTA-Cooperative PRMT5 Inhibitors | PRMT1, PRMT5, PRMT6 | ADORA1 3288/4885PDE1A 757/4885PDE1B 607/4885 |
| US-20210079003-A1 | MTA-Cooperative PRMT5 Inhibitors | PRMT5, PRMT1, PRMT3 | ADORA1 3269/4885PDE1A 1142/4885PDE1B 1283/4885 |
| US-20210078994-A1 | MTA-Cooperative PRMT5 Inhibitors | PRMT5, PRMT1, PRMT3 | ADORA1 3269/4885PDE1A 1142/4885PDE1B 1283/4885 |
| US-11492351-B2 | MTA-cooperative PRMT5 inhibitors | PRMT5, PRMT1, PRMT3 | ADORA1 3515/4885PDE1A 1483/4885PDE1B 1584/4885 |
| US-20230054883-A1 | MTA-Cooperative PRMT5 Inhibitors | PRMT5, PRMT1, PRMT3 | ADORA1 3269/4885PDE1A 1142/4885PDE1B 1283/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.